Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185809 · ClinicalTrials.gov registry record
Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 25
- Enrollment target
NCT00185809: Completed study, sponsored by Stanford University.
NCT00185809 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185809 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive iodine entering breast cancer cells, how long your cancer retains the agent as well as how much is taken up by other organs, particularly the thyroid gland.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2000-11 |
| Est. Completion | 2008-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00185809
The ClinicalTrials.gov registry entry for NCT00185809 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00185809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00185809 about?
NCT00185809 is a clinical study titled "Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study". The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly treat some breast cancers ...
What is the current status of trial NCT00185809?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2000-11. Estimated completion is 2008-08.
Who is sponsoring clinical trial NCT00185809?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.